Skip to main content

Table 1 The chi-square test of the relationship between risk score and clinical features in TCGA cohort

From: Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma

Clinical feature

Risk Score

c2

P

High risk n(%)

Low risk n(%)

Age

  

0.931

0.335

 >65

59 (46.46%)

68 (53.54%)

  

  ≤ 65

112 (51.85%)

104 (48.15%)

  

BMI

  

1.275

0.259

 >25

71 (46.41%)

82 (53.59%)

  

  ≤ 25

86 (52.76%)

77 (47.24%)

  

Family cancer history

  

0.149

0.7

 NO

29 (23.58%)

94 (76.42%)

  

 YES

19 (26.03%)

54 (73.97%)

  

Gender

  

2.032

0.154

 female

61 (55.45%)

49 (44.55%)

  

 male

110 (47.21%)

123 (52.79%)

  

Tumor status

  

10.08931

0.001

 tumor free

73 (40.78%)

106 (59.22%)

  

 with tumor

87 (58.39%)

62 (41.61%)

  

New tumor event

  

4.85

0.028

 no

71 (43.83%)

91 (56.17%)

  

 yes

94 (55.95%)

74 (44.05%)

  

Prior Malignancy

  

2.815

0.093

 no

160 (51.28%)

152 (48.72%)

  

 yes

11 (35.48%)

20 (64.52%)

  

Histologic Grade

  

14.724

<0.001

 G1–2

90 (42.06%)

124 (57.94%)

  

 G3–4

79 (63.71%)

45 (36.29%)

  

Stage

  

13.911

<0.001

 I-II

104 (43.70%)

134 (56.30%)

  

 III-IV

56 (67.47%)

27 (32.53%)

  

Vascular tumor

  

9.806

0.002

 none

76 (38.38%)

122 (61.62%)

  

 Micro-Macro

58 (57.43%)

43 (42.57%)

  

Race

  

0.003

0.96

 white

86 (50.89%)

83 (49.11%)

  

 asian-blank&Indian

83 (50.61%)

81 (49.39%)